Dateline City:
KENILWORTH, N.J.
Company Reaffirms Transaction To Proceed as Planned; Expected to Close in First Quarter of 2015
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the
following statement regarding the decision of the U.S. District Court
for the District of Delaware. The decision, which upheld the patent for
CUBICIN that expires on June 15, 2016 and invalidated four others, is
subject to appeal.
Language:
English
Contact:
MerckMedia:Lainie Keller, 908-236-5036orSteve Cragle, 908-740-1801orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more